The Acclarent acquisition provides Integra LifeSciences the chance to scale and seize leadership in the ENT device segment, enriching its innovative portfolio and providing shareholder value. In tandem with Integra's neurosurgery segment, it signifies a strategic move that will enhance innovation across ENT and other CSS technologies.